Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 10/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.51 |
| ▸ | SCD | O00767 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 2/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13696497 | 0.91 | SLC6A2 (0.49) | SLC6A2SLC6A3SLC6A4SCDEPHX2 | |
| SCHEMBL7701922 | 0.91 | SLC6A2 (0.49) | SLC6A2SLC6A3SLC6A4SCDEPHX2 | |
| SCHEMBL10525480 | 0.90 | SLC6A2 (0.47) | SLC6A2SLC6A3SLC6A4SCDEPHX2 | |
| SCHEMBL12180578 | 0.86 | KAT2B (0.56) | SLC6A2SLC6A3SLC6A4SCDEPHX2 | |
| SCHEMBL2088693 | 0.86 | SLC6A2 (0.45) | SLC6A2SLC6A3SLC6A4SCDEPHX2 | |
| SCHEMBL1229562 | 0.86 | HRH1 (0.62) | SLC6A2SLC6A3SLC6A4HTR2CHTR2B | |
| SCHEMBL30656257 | 0.85 | SCD (0.53) | SLC6A2SLC6A3SCDEPHX2HRH1 | |
| Hydrochloric Acid SCHEMBL3467493 | 0.85 | HRH1 (0.60) | SLC6A2SLC6A3SLC6A4HTR2CHTR2B | |
| SCHEMBL10274501 | 0.85 | SCD (0.53) | SLC6A2SLC6A3SCDEPHX2HRH1 | |
| SCHEMBL28418035 | 0.83 | HTR1A (0.50) | SLC6A2SLC6A3SLC6A4HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| WO-2023107552-A2 | PURINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-10793568-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | ARDELYX, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-10562884-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190233420-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. | 2019-08-01 | — | — | US | disclosed |
| US-20160272773-A1 | EXTRUDED POLYSTYRENE FOAM AND METHOD FOR MANUFACTURING SAME | KANEKA CORPORATION (JP) | 2016-09-22 | — | — | US | disclosed |
| US-9012111-B2 | Photo-curable resin composition, photo-curable dry film, patterning process, protective film, and electric/electronic part | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2015-04-21 | — | — | US | disclosed |
| EP-2594554-A1 | BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2013-05-22 | — | — | EP | disclosed |
| US-20130116227-A1 | BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20130116227-A1 | BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-05-09 | — | — | US | disclosed |
| WO-2012008435-A1 | BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 大日本住友製薬株式会社 (JP) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116227-A1 | BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | MC2R, NR3C2, REN | SLC6A2 358/4885SLC6A3 564/4885SLC6A4 686/4885 |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, MDM2 | SLC6A2 4767/4885SLC6A3 4723/4885SLC6A4 4720/4885 |
| US-10562884-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | SLC6A2 341/4885SLC6A3 524/4885SLC6A4 612/4885 |
| US-10793568-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | NR1H4, FXR1, GLP1R | SLC6A2 3748/4885SLC6A3 3436/4885SLC6A4 2737/4885 |
| US-20190233420-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | SLC6A2 3748/4885SLC6A3 3436/4885SLC6A4 2737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.